Optical coherence tomography in STEMI with bioresorbable scaffold: possible cause of coronary flow impairment? A sub-study from the Prague 19 trial.
Marco LoffiPetr TousekTomas BudesinskyLibor LisaAndrea SantangeloPetr WidimskyViktor KockaPublished in: Heart and vessels (2018)
This study assessed the Optical Coherence Tomography (OCT) impact on the coronary flow in ST-elevation myocardial infarction (STEMI) after bioresorbable scaffold implantation. Only few data about OCT use in STEMI are available and coronary flow before and after OCT is not well studied yet. 54 patients with OCT performed at the end of procedure from the Prague 19 trial were selected and coronary flow was evaluated as TIMI frame count (TFC) before and just after OCT. Significant increase in TIMI frame count after OCT [from 9.5 (6.75-12.25) to 11.5 (8-15.25) frames; p = 0.001] and high verapamil administration (18%) was reported. OCT at the end of primary percutaneous coronary intervention with bioresorbable scaffold is a feasible procedure. However, it seems to be associated with flow deterioration.
Keyphrases
- optical coherence tomography
- percutaneous coronary intervention
- st elevation myocardial infarction
- coronary artery disease
- diabetic retinopathy
- st segment elevation myocardial infarction
- optic nerve
- coronary artery
- acute myocardial infarction
- acute coronary syndrome
- coronary artery bypass grafting
- antiplatelet therapy
- study protocol
- clinical trial
- coronary artery bypass
- randomized controlled trial
- minimally invasive
- machine learning
- heart failure
- electronic health record
- open label
- transcatheter aortic valve replacement